Pharmaceuticals

Muscular dystrophy drug cost escalates to $89,000 per year

Muscular dystrophy drug cost escalates to $89,000 per year

Muscular dystrophy treatment from Marathon Pharmaceuticals LLC will cost $89,000 per year for patients in the United States.

Novo Nordisk Places $145 Billion Bet on Oxford University Diabetes Research Unit

Novo Nordisk Places $145 Billion Bet on Oxford University Diabetes Research Unit

Danish pharmaceutical giant Novo Nordisk has planned $145 billion investment in Oxford University’s diabetes research center. The money will be invested over a period of 10 years.

Gilead Sciences (GILD) Termed as Long Term Buy in Zacks Research Report

Gilead Sciences (GILD) Termed as Long Term Buy in Zacks Research Report

Gilead Sciences (GILD) has been among favorite stock of market analysts, especially after the company launched Hepatitis C treatment.

Novartis teams up with Rani Therapeutics to create robotic pill

Novartis teams up with Rani Therapeutics to create robotic pill

Swiss pharmaceuticals giant Novartis has teamed up with the U. S.-based Rani Therapeutics to create a robotic pill for complex biotech drugs.

Medical firms offering discount on Hepatitis C medication

Medical firms offering discount on Hepatitis C medication

Medical experts have said producers are offering substantial discounts on the only hepatitis C drug makers in the market as part of a prolonged price war in the industry.

Pfizer reports positive results for ROS1 positive lung cancer patients with Xalkori

Pfizer reports positive results for ROS1 positive lung cancer patients with Xalk

Medical researchers have announced positive results for Pfizer' Xalkori for non-small cell lung cancer patients.

Pages